vs
Side-by-side financial comparison of FGI Industries Ltd. (FGI) and NewAmsterdam Pharma Co N.V. (NAMS). Click either name above to swap in a different company.
FGI Industries Ltd. is the larger business by last-quarter revenue ($30.5M vs $19.1M, roughly 1.6× NewAmsterdam Pharma Co N.V.). FGI Industries Ltd. runs the higher net margin — -8.6% vs -90.7%, a 82.1% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs -14.4%). FGI Industries Ltd. produced more free cash flow last quarter ($2.3M vs $-37.8M).
FGI Industries Ltd is a global designer, manufacturer and distributor of kitchen and bath products, home organization solutions, and home improvement goods. It serves major retail chains, home specialty stores and e-commerce platforms across North America, Europe and the Asia-Pacific region.
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
FGI vs NAMS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $30.5M | $19.1M |
| Net Profit | $-2.6M | $-17.4M |
| Gross Margin | 26.7% | — |
| Operating Margin | -2.2% | -186.1% |
| Net Margin | -8.6% | -90.7% |
| Revenue YoY | -14.4% | 740.1% |
| Net Profit YoY | -553.1% | 55.5% |
| EPS (diluted) | $-1.63 | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.5M | — | ||
| Q3 25 | $35.8M | — | ||
| Q2 25 | $31.0M | $19.1M | ||
| Q1 25 | $33.2M | — | ||
| Q4 24 | $35.6M | $12.8M | ||
| Q3 24 | $36.1M | $29.1M | ||
| Q2 24 | $29.4M | — | ||
| Q1 24 | $30.8M | — |
| Q4 25 | $-2.6M | — | ||
| Q3 25 | $-1.7M | — | ||
| Q2 25 | $-1.2M | $-17.4M | ||
| Q1 25 | $-629.1K | — | ||
| Q4 24 | $-402.3K | $-92.2M | ||
| Q3 24 | $-550.1K | $-16.6M | ||
| Q2 24 | $163.6K | — | ||
| Q1 24 | $-412.2K | — |
| Q4 25 | 26.7% | — | ||
| Q3 25 | 26.5% | — | ||
| Q2 25 | 28.1% | — | ||
| Q1 25 | 26.8% | — | ||
| Q4 24 | 24.6% | — | ||
| Q3 24 | 25.8% | — | ||
| Q2 24 | 30.5% | — | ||
| Q1 24 | 27.4% | — |
| Q4 25 | -2.2% | — | ||
| Q3 25 | 1.0% | — | ||
| Q2 25 | -2.7% | -186.1% | ||
| Q1 25 | -3.9% | — | ||
| Q4 24 | -3.5% | -338.5% | ||
| Q3 24 | -0.2% | -85.9% | ||
| Q2 24 | -1.5% | — | ||
| Q1 24 | -1.0% | — |
| Q4 25 | -8.6% | — | ||
| Q3 25 | -4.6% | — | ||
| Q2 25 | -4.0% | -90.7% | ||
| Q1 25 | -1.9% | — | ||
| Q4 24 | -1.1% | -721.7% | ||
| Q3 24 | -1.5% | -57.2% | ||
| Q2 24 | 0.6% | — | ||
| Q1 24 | -1.3% | — |
| Q4 25 | $-1.63 | — | ||
| Q3 25 | $-0.86 | — | ||
| Q2 25 | $-0.64 | $-0.15 | ||
| Q1 25 | $-0.07 | — | ||
| Q4 24 | $-0.38 | $-0.91 | ||
| Q3 24 | $-0.29 | $-0.18 | ||
| Q2 24 | $0.08 | — | ||
| Q1 24 | $-0.04 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.9M | $739.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $17.3M | $778.5M |
| Total Assets | $69.5M | $815.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.9M | — | ||
| Q3 25 | $1.9M | — | ||
| Q2 25 | $2.5M | $739.2M | ||
| Q1 25 | $1.2M | — | ||
| Q4 24 | $4.6M | $834.2M | ||
| Q3 24 | $3.0M | $422.7M | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | $3.3M | — |
| Q4 25 | $17.3M | — | ||
| Q3 25 | $19.7M | — | ||
| Q2 25 | $21.3M | $778.5M | ||
| Q1 25 | $21.8M | — | ||
| Q4 24 | $22.3M | $757.5M | ||
| Q3 24 | $23.5M | $378.9M | ||
| Q2 24 | $23.8M | — | ||
| Q1 24 | $23.9M | — |
| Q4 25 | $69.5M | — | ||
| Q3 25 | $73.0M | — | ||
| Q2 25 | $71.7M | $815.1M | ||
| Q1 25 | $68.5M | — | ||
| Q4 24 | $75.5M | $864.6M | ||
| Q3 24 | $74.7M | $439.2M | ||
| Q2 24 | $69.9M | — | ||
| Q1 24 | $68.6M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.3M | $-37.7M |
| Free Cash FlowOCF − Capex | $2.3M | $-37.8M |
| FCF MarginFCF / Revenue | 7.5% | -197.2% |
| Capex IntensityCapex / Revenue | 0.2% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-212.5K | $-119.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.3M | — | ||
| Q3 25 | $-1.9M | — | ||
| Q2 25 | $7.6M | $-37.7M | ||
| Q1 25 | $-7.4M | — | ||
| Q4 24 | $617.4K | $-37.5M | ||
| Q3 24 | $-915.0K | $-12.5M | ||
| Q2 24 | $862.1K | — | ||
| Q1 24 | $-8.0M | — |
| Q4 25 | $2.3M | — | ||
| Q3 25 | $-2.1M | — | ||
| Q2 25 | $7.4M | $-37.8M | ||
| Q1 25 | $-7.7M | — | ||
| Q4 24 | $-214.1K | $-37.5M | ||
| Q3 24 | $-1.1M | $-12.6M | ||
| Q2 24 | $281.5K | — | ||
| Q1 24 | $-8.6M | — |
| Q4 25 | 7.5% | — | ||
| Q3 25 | -5.9% | — | ||
| Q2 25 | 23.8% | -197.2% | ||
| Q1 25 | -23.3% | — | ||
| Q4 24 | -0.6% | -293.5% | ||
| Q3 24 | -3.0% | -43.2% | ||
| Q2 24 | 1.0% | — | ||
| Q1 24 | -28.0% | — |
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.7% | — | ||
| Q2 25 | 0.7% | 0.5% | ||
| Q1 25 | 1.1% | — | ||
| Q4 24 | 2.3% | 0.0% | ||
| Q3 24 | 0.5% | 0.3% | ||
| Q2 24 | 2.0% | — | ||
| Q1 24 | 2.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 5.27× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FGI
| Sanitaryware | $19.1M | 63% |
| Shower System | $5.8M | 19% |
| Kitchen And Bath Other | $3.3M | 11% |
| Bath Furniture Products | $2.3M | 7% |
NAMS
Segment breakdown not available.
